Cargando…
Who Will Benefit from Charged-Particle Therapy?
Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages compared to conventional photon radiotherapy. As it can reduce the amount of radiation irradiated in the normal organ, CPT has been mainly applie...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291184/ https://www.ncbi.nlm.nih.gov/pubmed/34176253 http://dx.doi.org/10.4143/crt.2021.299 |
_version_ | 1783724599385522176 |
---|---|
author | Kim, Kyung Su Wu, Hong-Gyun |
author_facet | Kim, Kyung Su Wu, Hong-Gyun |
author_sort | Kim, Kyung Su |
collection | PubMed |
description | Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages compared to conventional photon radiotherapy. As it can reduce the amount of radiation irradiated in the normal organ, CPT has been mainly applied to pediatric cancer and radioresistent tumors in the eloquent area. Although there is a possibility of greater benefits, high set-up cost and dearth of high level of clinical evidence hinder wide applications of CPT. This review aims to present recent clinical results of PBT and CIRT in selected diseases focusing on possible indications of CPT. We also discussed how clinical studies are conducted to increase the number of patients who can benefit from CPT despite its high cost. |
format | Online Article Text |
id | pubmed-8291184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-82911842021-08-04 Who Will Benefit from Charged-Particle Therapy? Kim, Kyung Su Wu, Hong-Gyun Cancer Res Treat Special Article Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages compared to conventional photon radiotherapy. As it can reduce the amount of radiation irradiated in the normal organ, CPT has been mainly applied to pediatric cancer and radioresistent tumors in the eloquent area. Although there is a possibility of greater benefits, high set-up cost and dearth of high level of clinical evidence hinder wide applications of CPT. This review aims to present recent clinical results of PBT and CIRT in selected diseases focusing on possible indications of CPT. We also discussed how clinical studies are conducted to increase the number of patients who can benefit from CPT despite its high cost. Korean Cancer Association 2021-07 2021-06-21 /pmc/articles/PMC8291184/ /pubmed/34176253 http://dx.doi.org/10.4143/crt.2021.299 Text en Copyright © 2021 by the Korean Cancer Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Special Article Kim, Kyung Su Wu, Hong-Gyun Who Will Benefit from Charged-Particle Therapy? |
title | Who Will Benefit from Charged-Particle Therapy? |
title_full | Who Will Benefit from Charged-Particle Therapy? |
title_fullStr | Who Will Benefit from Charged-Particle Therapy? |
title_full_unstemmed | Who Will Benefit from Charged-Particle Therapy? |
title_short | Who Will Benefit from Charged-Particle Therapy? |
title_sort | who will benefit from charged-particle therapy? |
topic | Special Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291184/ https://www.ncbi.nlm.nih.gov/pubmed/34176253 http://dx.doi.org/10.4143/crt.2021.299 |
work_keys_str_mv | AT kimkyungsu whowillbenefitfromchargedparticletherapy AT wuhonggyun whowillbenefitfromchargedparticletherapy |